Stephen J. Schuster MD

• Healthcare
• Pharma & Biotech
• Switzerland

Novartis: Today’s FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of…